Accès ouvert
2026
article
OpenAlex
Claudia Manriquez-Roman, Elizabeth L. Siegler, Justyna J. Gleba, Truc N Huynh et autres
BACKGROUND: Antigen loss remains a major barrier to chimeric antigen receptor (CAR) T cell efficacy in solid tumors. In aggressive thyroid cancers, dedifferentiation is accompanied by coordinated loss of lineage-restricted surface antigens, limiting immune recognition. METHODS: Thyroid-stimulating hormone receptor (TSHR) expression was …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Omar L Gutierrez Ruiz, Jennifer M. Feigin, Brooke Kimball, R. Leo Sakemura et autres
Abstract Gastrointestinal (GI) cancers are rising in people < 50 and remain major causes of cancer mortality despite therapeutic advances. Chimeric antigen receptor T (CART) cell therapy has transformed treatment of hematological cancers. However, its efficacy in GI cancers has been hindered …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Grace DeFranco, Kun Yun, Claudia Manriquez Roman, Jennifer M. Feigin et autres
Abstract Chimeric antigen receptor T (CART) cell therapy has shown unprecedented success in the treatment of hematological malignancies. However, the immunosuppressive tumor microenvironment of both solid and liquid tumors is a major barrier for CART efficacy. Immunosuppressive myeloid cells inhibit CART efficacy. …
us, cn, fr
(code pays fourni par la source)